AC Immune gets $4M grant for Parkinson’s trial
AC Immune SA reported that it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AC Immune SA reported that it will receive a $4 million research grant from The Vijay and Marie Goradia Charitable Foundation. The funding will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, its anti‑alpha‑synuclein active immunotherapy, in early Parkinson’s disease.
The company highlights that the extended trial will help generate long‑term safety and efficacy data, particularly for prodromal and early Parkinson’s disease where prolonged treatment is expected. Management describes ACI‑7104 as showing promising interim Phase 2 results with favorable safety, strong antibody responses, target engagement and encouraging clinical signals, with final Part 1 data to week‑104 expected in H2 2026.
Positive
- $4 million research grant from The Vijay and Marie Goradia Charitable Foundation provides non‑dilutive funding to extend Part 1 of the Phase 2 VacSYn trial of ACI‑7104 in early Parkinson’s disease.
- Positive interim Phase 2 VacSYn results reported in December 2025 showed favorable safety, robust and boostable antibody responses, target engagement and encouraging clinical signals for ACI‑7104.
Negative
- None.
Insights
$4M grant provides non‑dilutive support to extend AC Immune’s key Parkinson’s trial.
The grant of $4 million from The Vijay and Marie Goradia Charitable Foundation directly funds an extension of Part 1 of the Phase 2 VacSYn trial of ACI‑7104 in early Parkinson’s disease. This helps AC Immune deepen its clinical dataset without raising equity or taking on debt.
The company notes positive interim Phase 2 results reported in December 2025, including a favorable safety profile, robust and boostable antibody responses, evidence of target engagement, and encouraging clinical signals. These findings support continued investment in the program while longer‑term outcomes are collected.
Final Part 1 results to week‑104 are expected in H2 2026, which will be an important clinical inflection point for understanding ACI‑7104’s potential disease‑modifying impact in early and prodromal Parkinson’s disease. Subsequent disclosures may clarify next‑step development plans based on those data.
Key Figures
Key Terms
Phase 2 VacSYn trial medical
active immunotherapy medical
alpha-synuclein medical
prodromal medical
disease-modifying effect medical
precision prevention medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AC Immune (ACIU) announce in its June 2026 Form 6-K?
How will the $4 million Goradia Foundation grant be used by AC Immune (ACIU)?
What is ACI-7104 in AC Immune’s (ACIU) Parkinson’s disease pipeline?
What interim Phase 2 results has AC Immune (ACIU) reported for ACI-7104?
When are final Part 1 results from AC Immune’s Phase 2 VacSYn trial expected?
How does AC Immune (ACIU) describe its broader business and pipeline focus?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission file number: 001-37891
AC IMMUNE SA
(Exact Name of Registrant as Specified in Its Charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| Form 20-F | ☒ | Form 40-F | ☐ |
On June 11, 2026, AC Immune SA issued a press release announcing that it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune’s anti-alpha-synuclein active immunotherapy, in early Parkinson’s disease. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release dated June 11, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AC IMMUNE SA | ||
| By: | /s/ Andrea Pfeifer | |
| Name: Andrea Pfeifer | ||
| Title: Chief Executive Officer | ||
| By: | /s/ Christopher Roberts | |
| Name: Christopher Roberts | ||
| Title: Chief Financial Officer | ||
|
Date: June 11, 2026 |
||
Exhibit 99.1
 |
PRESS RELEASE |
AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
| · | Grant supports extension of Part 1 of Phase 2 VacSYn trial of ACI-7104 |
| · | Planned extension of Part 1 will assess long-term safety and efficacy of ACI-7104 for an additional 2 years |
| · | Final data from Part 1 of VacSYn trial expected in H2 2026 |
Lausanne, Switzerland, June 11, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it will receive a research grant of $4 million from The Vijay and Marie Goradia Charitable Foundation. The grant will support extending Part 1 of the ongoing Phase 2 VacSYn trial of ACI-7104, AC Immune’s anti-alpha-synuclein (a-syn) active immunotherapy, in early Parkinson’s disease (PD).
Houston businessman, philanthropist, and cancer survivor Vijay Goradia and his wife, Marie, established the Vijay and Marie Goradia Charitable Foundation to support health, education, and human services. The Foundation has previously awarded substantial grants to the University of Texas MD Anderson Cancer Center to speed translational research and clinical trials.
The long-term dataset enabled by this grant will be particularly valuable for individuals with prodromal and early PD, who will likely require prolonged treatment and are expected to benefit from a well-established long-term safety profile.
Vijay Goradia commented: “It is our hope that this grant will contribute to expanding our knowledge of PD and to bringing ACI-7104 to patients in the earliest stages of disease, before its symptoms have irreversibly changed the lives of patients and their families. If realized, its potential to slow the rate of progression would revolutionize the treatment of PD, preserving function and independence for individuals and bringing hope to millions. We are particularly excited and hopeful about the future potential for ACI-7104 to prevent PD, sparing other families from this disease altogether.”
Dr. Andrea Pfeifer, CEO of AC Immune SA, commented: “We are honored to receive this grant from The Vijay and Marie Goradia Charitable Foundation. ACI-7104 is showing considerable promise in clinical testing. I would like to thank Vijay and Marie Goradia both for their generous contribution and for their recognition of the potential of ACI-7104 as AC Immune continues to advance towards precision prevention of neurodegenerative diseases, including PD.”
Martin Zügel, MD, interim CEO designate of AC Immune and Chair of the Board of Directors, commented: “We thank The Vijay and Marie Goradia Charitable Foundation for this grant in support of our efforts to develop ACI-7104 in early-stage PD. The grant will significantly impact the extension of Part 1 of the VacSYn trial and enable us to generate vital long-term data on the use of the product in patients.”
| PRESS RELEASE |
Positive interim results from the Phase 2 VacSYn trial of ACI-7104 in early PD were reported in December 2025. These data suggested that targeting a-syn pathology with an active immunotherapy could potentially have a disease-modifying effect and thus slow the rate of progression of PD. The interim results also indicated a favorable safety profile, robust and boostable antibody responses, evidence of target engagement, and encouraging clinical signals. Final results from Part 1 of the trial (to week-104) are expected in H2 2026.
About ACI-7104.056
ACI-7104.056 is an optimized formulation of its clinically validated anti-a-syn predecessor active immunotherapy which generated a target-specific antibody response against pathological oligomeric a-syn to inhibit spreading and downstream neurodegeneration in early Parkinson’s disease. The accumulation of alpha-synuclein protein aggregates has been shown to cause inflammatory stress in cells and contribute to the degeneration of neurons in the brain. It has been known to play a key role in the development of neurodegenerative diseases such as Parkinson’s Disease.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
SVP, Investor Relations & Corporate Communications
Gary Waanders, Ph.D., MBA
AC Immune
Phone: +41 21 345 91 91
Email: gary.waanders@acimmune.com
International Media
Chris Maggos
Cohesion Bureau
Phone: +41 79 367 6254
Email: chris.maggos@cohesionbureau.com
| PRESS RELEASE |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.